Follow
Junming Yie
Title
Cited by
Cited by
Year
Ordered recruitment of chromatin modifying and general transcription factors to the IFN-β promoter
T Agalioti, S Lomvardas, B Parekh, J Yie, T Maniatis, D Thanos
Cell 103 (4), 667-678, 2000
9992000
Structure of IRF-1 with bound DNA reveals determinants of interferon regulation
CR Escalante, J Yie, D Thanos, AK Aggarwal
Nature 391 (6662), 103-106, 1998
4721998
Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15
JY Hsu, S Crawley, M Chen, DA Ayupova, DA Lindhout, J Higbee, ...
Nature 550 (7675), 255-259, 2017
4492017
Acetylation of HMG I (Y) by CBP turns off IFNβ expression by disrupting the enhanceosome
N Munshi, M Merika, J Yie, K Senger, G Chen, D Thanos
Molecular cell 2 (4), 457-467, 1998
4421998
Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms
E Mueller, S Drori, A Aiyer, J Yie, P Sarraf, H Chen, S Hauser, ED Rosen, ...
Journal of Biological Chemistry 277 (44), 41925-41930, 2002
3362002
Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN
EY Tsai, J Yie, D Thanos, AE Goldfeld
Molecular and Cellular Biology 16 (10), 5232-5244, 1996
2571996
The role of HMG I (Y) in the assembly and function of the IFN-β enhanceosome
J Yie, M Merika, N Munshi, G Chen, D Thanos
The EMBO journal 18 (11), 3074-3089, 1999
2401999
FGF21 N-and C-termini play different roles in receptor interaction and activation
J Yie, R Hecht, J Patel, J Stevens, W Wang, N Hawkins, S Steavenson, ...
FEBS letters 583 (1), 19-24, 2009
2222009
Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes
R Hecht, YS Li, J Sun, E Belouski, M Hall, T Hager, J Yie, W Wang, ...
PloS one 7 (11), e49345, 2012
1852012
Intra-and intermolecular cooperative binding of high-mobility-group protein I (Y) to the beta-interferon promoter
J Yie, S Liang, M Merika, D Thanos
Molecular and cellular biology 17 (7), 3649-3662, 1997
1681997
Mechanism by which the IFN-β enhanceosome activates transcription
J Yie, K Senger, D Thanos
Proceedings of the national academy of Sciences 96 (23), 13108-13113, 1999
1651999
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
EA Killion, J Wang, J Yie, SDH Shi, D Bates, X Min, R Komorowski, ...
Science Translational Medicine 10 (472), eaat3392, 2018
1512018
Understanding the Physical Interactions in the FGF21/FGFR/β‐Klotho Complex: Structural Requirements and Implications in FGF21 Signaling
J Yie, W Wang, L Deng, LT Tam, J Stevens, MM Chen, Y Li, J Xu, ...
Chemical biology & drug design 79 (4), 398-410, 2012
1142012
Gene repression by coactivator repulsion
K Senger, M Merika, T Agalioti, J Yie, CR Escalante, G Chen, ...
Molecular cell 6 (4), 931-937, 2000
1032000
The IFN-β enhancer: a paradigm for understanding activation and repression of inducible gene expression
N Munshi, J Yie, M Merika, K Senger, S Lomvardas, T Agalioti, D Thanos
Cold Spring Harbor symposia on quantitative biology 64, 149-160, 1999
851999
A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys
S Stanislaus, R Hecht, J Yie, T Hager, M Hall, C Spahr, W Wang, ...
Endocrinology 158 (5), 1314-1327, 2017
842017
Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation
J Xu, J Bussiere, J Yie, A Sickmier, P An, E Belouski, S Stanislaus, ...
Bioconjugate chemistry 24 (6), 915-925, 2013
782013
Antibodies to myostatin
ER Chin, LL Green, C Ibebunjo, PA Krasney, J Yie, J Zachweija
US Patent 7,807,159, 2010
752010
Antibodies to myostatin
ER Chin, LL Green, C Ibebunjo, PA Krasney, J Yie, J Zachweija
US Patent 7,807,159, 2010
752010
Antibodies to myostatin
ER Chin, LL Green, C Ibebunjo, PA Krasney, J Yie, J Zachweija
US Patent 7,807,159, 2010
752010
The system can't perform the operation now. Try again later.
Articles 1–20